Pitfall of hepatitis B surface antigen testing in a kidney transplant recipient presenting hepatitis B reactivation

Clinics and Research in Hepatology and Gastroenterology

Volumn 35, Issue 10, 2011, Pages 671-674

  Romanet, Pauline ^a   Vacher Coponat, Henri ^c   Moal, Valérie ^c   Botta Fridlund, Danielle ^c   Motte, Anne ^a   Colson, Philippe ^a,b  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITÉ   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; SULFAMETHOXAZOLE; TACROLIMUS; TRIMETHOPRIM; VALGANCICLOVIR;

ACUTE PYELONEPHRITIS; AGED; ANTIBODY TITER; ARTICLE; CASE REPORT; DIABETES CONTROL; FALSE POSITIVE RESULT; GRAFT RECIPIENT; HEMODIALYSIS; HEPATITIS B; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MALE; REAL TIME POLYMERASE CHAIN REACTION; SEROLOGY; TREATMENT DURATION; VACCINATION;

AGED; FALSE POSITIVE REACTIONS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; MALE; RECURRENCE;

EID: 80054868097     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2011.05.006     Document Type: Article

References (17)

1. Carman W.F. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 1997, 4(Suppl. 1):11-20.
2. Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol 2005, 32(2):102-112.
3. Ly T.D., Servant-Delmas A., Bagot S., Gonzalo S., Férey M.P., Ebel A., et al. Sensitivities of four new commercial hepatitis B virus surface antigen (HBsAg) assays in detection of HBsAg mutant forms. J Clin Microbiol 2006, 44(7):2321-2326.
4. Le Pendeven C., Cuzon G., Fontaine H., Zatla F., Schneider V., Amiel C., et al. Hepatitis B escape mutant reactivation in a renal transplant patient. J Clin Virol 2007, 40(1):74-76.
5. Yeo W., Chan T.C., Leung N.W., Lam W.Y., Mo F.K., Chu M.T., et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009, 27(4):605-611.
6. Murakami R., Amada N., Sato T., Orii T., Kikuchi H., Haga I., et al. Reactivation of hepatitis and lamivudine therapy in 11 HBsAg-positive renal allograft recipients: a single centre experience. Clin Transplant 2006, 20(3):351-358.
7. Borentain P., Colson P., Coso D., Bories E., Charbonnier A., Stoppa A.M., et al. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. J Viral Hepat 2010, 17(11):807-815.
8. Diagnosis and virological follow up of viral hepatitis (except of screening of blood, organs or tissue donors) 2001. ANAES Recommandations 2001. Gastroenterol Clin Biol 2003, 27:177-200. ANAES.
9. Colson P., Borentain P., Motte A., Henry M., Moal V., Botta-Fridlund D., et al. Clinical and virological significance of the co-existence of HBsAg and anti-HBs antibodies in hepatitis B chronic carriers. Virology 2007, 367(1):30-40.
10. Moal V., Vacher-Coponat H., Botelho E., Berland Y., Colson P., Tamalet C., et al. Emergence of hepatitis B infection despite antibodies to hepatitis B surface antigen: a new nosocomial risk in patients with end-stage renal disease. Transplantation 2006, 81(9):1358-1359.
11. Lada O., Benhamou Y., Poynard T., Thibault V. Coexistence of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of " a" determinant variants. J Virol 2006, 80(6):2968-2975.
12. Lu M., Lorentz T. De novo infection in a renal transplant recipient caused by novel mutants of hepatitis B virus despite the presence of protective anti-hepatitis B surface antibody. J Infect Dis 2003, 187(8):1323-1326.
13. Grotz W., Rasenack J., Benzing T., Berthold H., Peters T., Walter E., et al. Occurrence and management of hepatitis B virus reactivation following kidney transplantation. Clin Nephrol 1998, 49(6):385-388.
14. Kim K.H., Ahn S.H., Chung H.Y., Paik Y.H., Lee K.S., Kim Y.S., et al. Hepatitis B virus infection after renal transplantation in the presence of antibody to hepatitis B surface antigen immunity. J Gastroenterol Hepatol 2004, 19(8):847-853.
15. Fairley C.K., Mijch A., Gust I.D., Nichilson S., Dimitrakakis M., Lucas C.R. The increased risk of fatal liver disease in renal transplant patients who are hepatitis Be antigen and/or HBV DNA positive. Transplantation 1991, 52(3):497-500.
16. Chen D., Kaplan L.A. Performance of a new-generation chemiluminescent assay for hepatitis B surface antigen. Clin Chem 2006, 52(8):1592-1598.
17. O'Brien J.E. Hepatitis B surface antigen: decreased need for confirmation of reactive results. Clin Chem 2000, 46(4):582.